Literature DB >> 17695495

Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates.

Natalja Inzkirweli1, Brigitte Gückel, Christof Sohn, Diethelm Wallwiener, Gunther Bastert, Matthias Lindner.   

Abstract

BACKGROUND: Loading of dendritic cells (DCs) with tumor cell (TC) preparations is an attractive method for vaccine preparation because the entire antigen repertoire of a tumor is processed and presented by the DCs, thus allowing the simultaneous stimulation of T-helper cells and cytotoxic T-lymphocytes. However, optimal loading conditions have still to be defined.
MATERIALS AND METHODS: DCs were pulsed either with tumor lysates, apoptotic or necrotic preparations of a breast cancer cell line and subsequently used to stimulate autologous T-lymphocytes. Antigen loading was quantified using immunofluorescent-based methods.
RESULTS: Four hours co-incubation of apoptotic TCs or tumor lysates with DCs undergoing maturation resulted in effective DC-loading. However, the DCs pulsed with apoptotic TCs were best in stimulating interferon-gamma (INF-gamma) secretion as the effector function of autologous T-cells.
CONCLUSION: Tumor lysates are in common use for DC-based vaccine manufacturing. However, our data indicate an advantage of apoptotic TC-preparations in regard to antigen loading effectiveness as well as the loaded DC's capacity to activate T-cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17695495

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  9 in total

1.  Low-dose chemotherapeutic agents regulate small Rho GTPase activity in dendritic cells.

Authors:  Galina V Shurin; Irina L Tourkova; Michael R Shurin
Journal:  J Immunother       Date:  2008-06       Impact factor: 4.456

2.  Dendritic cell immunotherapy induces anti-tumor effect in a transgenic mouse model of pancreatic ductal adenocarcinoma.

Authors:  Jia Yang; Su Hu; Junjie Shangguan; Aydin Eresen; Yu Li; Liang Pan; Quanhong Ma; Yuri Velichko; Jian Wang; Chunhong Hu; Vahid Yaghmai; Zhuoli Zhang
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

3.  Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells.

Authors:  Antje Hoff; Ana-Cristina Bagû; Thomas André; Günter Roth; Karl-Heinz Wiesmüller; Brigitte Gückel; Roland Brock
Journal:  Cancer Immunol Immunother       Date:  2010-05-29       Impact factor: 6.968

4.  Recognition of live phosphatidylserine-labeled tumor cells by dendritic cells: a novel approach to immunotherapy of skin cancer.

Authors:  Michael R Shurin; Alla I Potapovich; Yulia Y Tyurina; Irina L Tourkova; Galina V Shurin; Valerian E Kagan
Journal:  Cancer Res       Date:  2009-03-10       Impact factor: 12.701

5.  Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?

Authors:  Laetitia Cicchelero; Sofie Denies; Bert Devriendt; Hilde de Rooster; Niek N Sanders
Journal:  Oncoimmunology       Date:  2015-06-01       Impact factor: 8.110

Review 6.  Gene carriers and transfection systems used in the recombination of dendritic cells for effective cancer immunotherapy.

Authors:  Yu-Zhe Chen; Xing-Lei Yao; Yasuhiko Tabata; Shinsaku Nakagawa; Jian-Qing Gao
Journal:  Clin Dev Immunol       Date:  2010-12-20

Review 7.  Dendritic cell-based vaccination in cancer: therapeutic implications emerging from murine models.

Authors:  Soledad Mac Keon; María Sol Ruiz; Silvina Gazzaniga; Rosa Wainstok
Journal:  Front Immunol       Date:  2015-05-20       Impact factor: 7.561

8.  Engulfment of activated apoptotic cells abolishes TGF-β-mediated immunoregulation via the induction of IL-6.

Authors:  Clare A Notley; Mark A Brown; Jenny L McGovern; Christine K Jordan; Michael R Ehrenstein
Journal:  J Immunol       Date:  2015-01-19       Impact factor: 5.422

9.  HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy.

Authors:  Janet Kerstin Peper; Hans-Christian Bösmüller; Heiko Schuster; Brigitte Gückel; Helen Hörzer; Kevin Roehle; Richard Schäfer; Philipp Wagner; Hans-Georg Rammensee; Stefan Stevanović; Falko Fend; Annette Staebler
Journal:  Oncoimmunology       Date:  2015-07-01       Impact factor: 8.110

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.